title: Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants.
authors.affiliation: Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France. Electronic address: sebastien.gaertner@chru-strasbourg.fr.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Gaertner
authors.affiliation: Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.
authors.forename: Elena-Mihaela
authors.initials: EM
authors.lastname: Cordeanu
authors.affiliation: Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.
authors.forename: Corina
authors.initials: C
authors.lastname: Mirea
authors.affiliation: Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Stephan
mesh_terms: D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D004562:Electrocardiography; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010630:Phenindione / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069552:Rivaroxaban / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced* / Q000188:drug therapy; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014812:Vitamin K; D010630:Phenindione; D000069552:Rivaroxaban; C017673:fluindione
keywords: Atrial fibrillation; Hypercoagulable state; Stroke; Vitamin K antagonist